Long COVID, Long Covid19
Conditions
Brief summary
Long COVID (LC) affects an estimated 5-10% of individuals with SARS-CoV-2 causing a persistent physical, cognitive, and functional impairment with potentially severe socioeconomic consequences. While RECOVER-Adult cycle 1 established the largest, most comprehensive U.S. adult LC cohort (14,730 participants), key questions remain about long-term disease trajectories, biological mechanisms, and late-emerging complications. RECOVER-Adult cycle 2 will follow selected participants for two years each, focusing on neurocognitive, cardiopulmonary and infection-associated chronic conditions (IACC) such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and autonomic dysfunction. Using a case-cohort design, the study will investigate disease persistence versus resolution, biological mechanisms, and onset of new chronic illnesses, generating critical insights to guide prevention, treatment, and public health policy.
Interventions
None listed
Sponsors
NYU Langone Health
National Heart, Lung, and Blood Institute (NHLBI)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* RECOVER-Adult 2024 LCRI 11 or greater, as defined by Geng et al, 2024;1 or * At least 1 RECOVER-Adult LCRI symptom and either a) poor quality of life (QoL) as defined by a response of "poor" on the PROMIS-10 QoL question or b) "bother scale" is "quite a bit" or "very much" for corresponding LCRI symptom; or * At least 1 National Academies of Sciences, Engineering, and Medicine (NASEM) common symptom and either a) poor QoL, or b) "bother scale" is "quite a bit" or "very much" for corresponding NASEM symptom.
Exclusion criteria
* Individuals who have a known or documented hemoglobin lower than 8.5 g/dL, * Individuals who have not yet reached the age of majority, * Individuals who are unable to provide consent, * Individuals who are unwilling to consent to biospecimen collection or are unwilling to participate in the complete protocol, including all assessments and the cycle 2 visit schedule. Note that there are no exclusions related to blood volume collection. For healthy adults, the volume of blood collected (70.9 mL per visit and per year) is substantially lower than the federal minimal risk limit of 550 mL within 8 weeks, * Individuals in hospice care, * Individuals with a serious medical condition which would prevent in-person participation, * Individuals participating in the study NIH RECOVER-Pediatric: Understanding the long-term impact of COVID on children and families, unless enrolled only as caregiver, or * Long-term incarcerated individuals
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Long COVID Research Index (LCRI) Score of 11 or Higher | Baseline, Month 6, Month 12, Month 18, Month 24 | The LCRI 11 assesses symptoms such as malaise, brain fog, and fatigue to classify individuals into likely LC, possible LC, or no LC. A score of 11 or greater indicates high-symptom cases of LC. |
| Percentage of Participants with LC Remission | Month 6, Month 12, Month 18, Month 24 | Percentage of participants who experience remission from LC. |
| Percentage of Participants with New Onset Conditions | Month 6, Month 12, Month 18, Month 24 | New onset conditions include, but are not limited to, dementia, coronary artery disease, diabetes, renal disease, cancer, and myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patient-Reported Outcomes Measurement Information System Global Health-10 (PROMIS-10) Score | Baseline, Month 6, Month 12, Month 18, Month 24 | is a 10-item, patient-reported survey assessing overall physical, mental, and social health-related quality of life (QOL). The raw score is converted to a standardized t-score ranging from 0-100 (with a mean of 50 and standard deviation of 10); higher scores indicate more of the concept being measured (i.e., higher quality of life). |
Countries
United States
Contacts
CONTACTLeora Horwitz, MD
CONTACTPriscilla Short, CIP, CCRP
PRINCIPAL_INVESTIGATORLeora Horwitz, MD
NYU Langone Health
Outcome results
None listed